Researchers conducted a study to determine the rates of human papillomavirus (HPV) infection among adolescent girls and young women in New York City who received the HPV vaccine following its approval in 2007.
Researchers examined the efficacy and safety of the quadrivalent human papillomavirus vaccine for young men who have sex with men and are living with HIV.
Study authors assessed the relationship between quadrivalent HPV vaccination and risk of invasive cervical cancer and age of vaccination.
Clinicians must consider patient sexual history in the decision-making process for adult HPV vaccination.
The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.
Extending the current human papillomavirus (HPV) vaccination program to age 45 years is expected to produce small additional reductions in HPV-associated diseases with high additional costs.
Mailing human papillomavirus (HPV) kits to underscreened women is associated with increased screening uptake but does not significantly increase precancer detection or treatment.
In 2012 to 2016, an estimated 92% of cancers attributable to HPV were due to HPV types targeted by the 9vHPV vaccine.
Educational interventions delivered in a clinical setting may improve vaccination behaviors.
Parents of racial or ethnic minority adolescents were more likely to inaccurately report HPV vaccination initiation.
